<DOC>
	<DOCNO>NCT00746434</DOCNO>
	<brief_summary>The aim proof concept study show safety efficacy 0.5 % dermal roflumilast cream treatment plaque psoriasis adult . This multicenter , randomize , double-blind , placebo-controlled , parallel group study . 3-10 % body surface area ( BSA ) cover mild moderate form plaque psoriasis . In 4-week treatment period 76 mg cream apply two time daily 2 % BSA . After screen phase , washout phase flexible duration ( max 30 day , time depend upon pre-medication ) , 28 day treatment phase follow . As roflumilast potent anti-inflammatory substance , positive effect form dermal disease anticipate .</brief_summary>
	<brief_title>A Proof Concept Study With 0.5 % Roflumilast Cream Patients With Mild Moderate Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Patient ( able read , write fully understand English language ) inform verbally write objective clinical study , method , anticipate benefit potential risk discomfort he/she may expose , give write consent participation study prior study start studyrelated procedure . Patient suffer mild moderate plaque psoriasis Male female patient ethnic origin , age 18 year old present minimum 3 % maximum 10 % BSA affect mild moderate plaque psoriasis proven dermatologist . Patient must minimum 1 maximum 3 severity score psoriasis Patient must least one target lesion least 1 % BSA . Patient must willing wash current active therapy least 14 day prior Day 1 . Women childbearing potential must negative pregnancy test Screening Baseline Visits agree use highly effective method birth control . A highly effective method birth control define result low failure rate ( i.e . le 1 % per year ) use consistently correctly implant , injectables , combine oral contraceptive , IUDs , sexual abstinence vasectomise partner Patient spontaneously improve rapidly deteriorate plaque psoriasis within least past 3 month . Patients known history psoriasis unresponsive topical treatment . Patient physical condition ( e.g. , atopic dermatitis , contact dermatitis , tinea corporis ) , Investigator 's opinion , might impair evaluation plaque psoriasis expose patient unacceptable risk trial participation . Clinically relevant abnormal laboratory value vital sign suggest unknown underlying disease require clinical evaluation ( assessed Investigator ) . Patient pregnant , nurse plan pregnancy trial period . Patient currently enrol investigational drug device trial . Patient receive investigational drug investigational device within 30 day prior trial start . Patient history allergic reaction roflumilast inactive ingredient trial medication . Patient positive result virology test acute chronic infectious HIV hepatitis virus infection . Abuse alcohol drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Mild plaque psoriasis ,</keyword>
	<keyword>Moderate plaque psoriasis ,</keyword>
	<keyword>0.5 % Roflumilast cream</keyword>
</DOC>